Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 372 Show results per page	View Search Criteria \| Help With Results

Last Modified: 11/1/1997


1.		Phase II/III Pilot Treatment of Pediatric Non-B, Non-T ALL in First Marrow Relapse (SIMAL #8): Intensive Re-Induction and Reconsolidation Chemotherapy with Subsequent Myeloablative Chemoradiotherapy and Rescue with Either Allogeneic or In Vitro-Purged Autologous Marrow (Summary Last Modified 11/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				under 21 at relapse				NCI				POG-9410 POG-SIMAL-8, POG-9410

Last Modified: 7/1/1990


2.		Phase II/III Pilot Combination Chemotherapy with ARA-C/VP-16/IPP plus Mesna plus Intrathecal MTX in Pediatric Patients with Recurrent Nonlymphoblastic Lymphoma (Summary Last Modified 07/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				under 18				NCI				NCI-85-C-62 NCI-T85-0096N, T85-0096

Last Modified: 5/1/1990


3.		Phase II/III Chemotherapy with IPP plus Mesna/MTX/CF/ADR/CDDP with Surgery for Patients with Osteosarcoma or Fibrosarcoma of the Bone Who Have Had No Prior Chemotherapy (Summary Last Modified 05/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				under 25				NCI				SJCRH-OS-86 NCI-T86-0086D, T86-0086

Last Modified: 4/5/2007


4.		Phase II/III Study of L-PAM or IPP/Mesna, Followed by Conventional Chemotherapy with VCR/CTX/ADR plus CTX/VCR/ACT-D/ADR, Surgery, and Radiotherapy, for Stage IIB/IIC/IIIA/IIIB Rhabdomyosarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				under 18				NCI				SJCRH-RMS-V NCI-T86-0152D, T86-0152

Last Modified: 4/12/2007


5.		Phase II Evaluation of IPP, CBDCA, CHIP, and epi-ADR as Single Agents Prior to Phase III Randomized Comparison of CECA (CACP/VP-16/CTX/ADR) vs High-Dose CACP/VP-16/CTX/ADR in Children Aged at Least 365 Days with Previously Untreated Stage D Neuroblastoma and Phase III Multimodal Treatment of Stage C Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				1 to 21				NCI				POG-8741/42 POG-8741, POG-8742, POG-8741/42

Last Modified: 4/1/1997


6.		Phase II/III Induction Chemotherapy with IPP in Patients with Untreated Metastatic or Nonresectable Primary Osteosarcoma or Recurrent Osteosarcoma (Summary Last Modified 04/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				under 31				NCI				POG-8759 POG-8759

Last Modified: 7/1/1988


7.		Phase II/III Evaluation of IPP and VM-26 as Single Agents vs Combination Chemotherapy with CAV (CTX/ADR/VCR) in Patients with Extensive Small Cell Lung Cancer (Summary Last Modified 07/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				18 and over				NCI				EST-1588 EST-1588

Last Modified: 11/26/2007


8.		Phase II/III Randomized Comparison of Consolidation with Intensive Chemotherapy Using CDDP/VP-16/DOX/IFF vs Myeloablative Chemoradiotherapy and Autologous Marrow Rescue and of Continuation Therapy with Isotretinoin vs No Further Therapy in High-Risk Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				0 to 18				NCI				CCG-3891 CCG-3891

Last Modified: 2/8/2008


9.		Phase III Randomized Study of Incorporating IFF into Neoadjuvant and Adjuvant DOX/CDDP/MTX Chemotherapy and of MTP-PE During and After Maintenance Chemotherapy in Newly Diagnosed, Resectable Osteogenic Sarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				not over 30				NCI				CCG-7921 POG-9351, INT-0133

Last Modified: 6/23/2008


10.		Phase III Randomized Study of CDDP/IFF vs BIP (BLEO/IFF/CDDP) in Patients with Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				any age				NCI				GOG-149 GOG-0149

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute